Abby Hardy, Author at BioTuesdays

Feature

Hepion Pharmaceuticals’ CEO Robert Foster discusses CRV431’s potential in NASH

Hepion Pharmaceuticals (NASDAQ:HEPA), which recently changed its name from ContraVir Pharmaceuticals, is developing targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic...

July 30, 2019

Developments

FDA clears Hepion Pharma’s IND for CRV431 for the treatment of NASH

The FDA has authorized Hepion Pharmaceuticals (NASDAQ:HEPA) to proceed with its IND opening study of CRV431 for the treatment of non-alcoholic steatohepatitis (NASH). “Based on the preclinical and clinical studies we’ve...

July 29, 2019

Developments

Aeglea BioTherapeutics gets FDA breakthrough designation for pegzilarginase

Aeglea BioTherapeutics’ (NASDAQ:AGLE) pegzilarginase received FDA breakthrough therapy designation for the treatment of arginase 1 deficiency (ARG1-D). ARG1-D is a rare genetic childhood disease that causes severe...

July 25, 2019

Developments

Matinas gets FDA fast track, QIDP designations for MAT2203

The FDA granted fast track and qualified infectious disease product (QIDP) designations to Matinas BioPharma’s (NYSE AMER:MTNB) MAT2203 for the treatment of cryptococcal meningitis. MAT2203 is a lipid nano-crystal...

July 25, 2019

Markets

Stifel cuts Vanda Pharma to hold; PT to $17 from $26

Stifel downgraded Vanda Pharmaceuticals (NASDAQ:VNDA) to “hold” from “buy” and cut its price target to $17 from $26 after a deeper look into a FDA lawsuit against the company, its pipeline and execution risk. The stock...

July 25, 2019

Developments

Myovant’s relugolix meets primary endpoint in Phase 3 uterine fibroid trial

Myovant Sciences (NASDAQ:MYOV) reported that the second of two Phase 3 studies of relugolix met its primary efficacy endpoint and six key secondary endpoints in women with uterine fibroids. Relugolix is a once daily...

July 24, 2019

Developments

Dawson James starts Anavex at buy: PT $16

Dawson James initiated coverage of Anavex Life Sciences (NASDAQ:AVXL) with a “buy” rating and $16 price target. The stock closed $2.54 on July 23. Anavex is pioneering a new treatment in CNS diseases like...

July 24, 2019

Developments

Zenabis outperforms cannabis design capacity by 41% in June

Zenabis Global (TSX:ZENA) reported that its cultivation output in June 2019 was 756 kg of dried cannabis, which represents a 40.8% outperformance relative to design capacity, or a performance ratio of 40.8%. June 2019...

July 24, 2019

Developments

Emerging liver disease company, ContraVir, changes name to Hepion Pharmaceuticals; stock symbol to “HEPA”

ContraVir Pharmaceuticals (NASDAQ:CTRV) announced a name change to Hepion Pharmaceuticals, and a stock symbol change to “HEPA,” effective as of opening of trading on July 23, 2019. “We derived the name “Hepion” by...

July 22, 2019

Developments

Theravance reports new Phase 2 data for ampreloxetine

Theravance Biopharma (NASDAQ:TPBH) reported new data from its Phase 2 trial of ampreloxetine in patients with neurogenic orthostatic hypotension (nOH). nOH is characterized by a fall in systolic or diastolic blood...

July 22, 2019

Author - Abby Hardy

Hepion Pharmaceuticals’ CEO Robert Foster discusses CRV431’s potential in NASH

FDA clears Hepion Pharma’s IND for CRV431 for the treatment of NASH

Aeglea BioTherapeutics gets FDA breakthrough designation for pegzilarginase

Matinas gets FDA fast track, QIDP designations for MAT2203

Stifel cuts Vanda Pharma to hold; PT to $17 from $26

Myovant’s relugolix meets primary endpoint in Phase 3 uterine fibroid trial

Dawson James starts Anavex at buy: PT $16

Zenabis outperforms cannabis design capacity by 41% in June

Emerging liver disease company, ContraVir, changes name to Hepion Pharmaceuticals; stock symbol to “HEPA”

Theravance reports new Phase 2 data for ampreloxetine

Subscribe